News Archive

Novavax Inc. plans to advance its Covid-19 vaccine candidate with new additions to the company and about $200 million in new funds from selling convertible preferred stock — the latest cash infusion for the Gaithersburg vaccine maker.

The preferred private placement with a Boston-based RA Capital Management investment fund, in a deal that closed June 16, came fewer than two weeks after Novavax (NASDAQ: NVAX) won a Department of Defense contract worth up to $60 million to help manufacture its coronavirus vaccine candidate. It also builds upon $388 million Novavax landed from the Norway-based Coalition for Epidemic Preparedness Innovations for the same program. And it follows the company’s preparations to sell up to $250 million in common stock, a move that sent its stock soaring toward the end of May.

ROCKVILLE, Md. & SAN DIEGO–(BUSINESS WIRE)–Replicate Bioscience, Inc. (“Replicate”), a privately-held biopharmaceutical company creating novel treatments to prevent drug resistance in cancers, and Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that the companies have entered into a research and licensing option agreement to combine their platform technologies to combat infectious diseases and cancers.

NEWARK, Del., June 24, 2020 /PRNewswire/ — Today, the National Institute for Innovation in Manufacturing Biopharmacueticals (NIIMBL) announces that they have identified nine projects to allocate approximately $8.9 million from the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) award received in May 2020 towards the support the nation’s response to the COVID-19 pandemic.

In 2012, there were fewer than 1,400 maternal-fetal medicine specialists in the United States, and 98% resided inmetropolitan areas.

This left pregnant patients in rural areas without the ability to access care, especially if travel was not an option. 

Today, telehealth can be used to fill that gap – but providers still may face challenges in ensuring patients get the services they need.

George Petrocheilos and R. Jacob Vogelstein have left Camden Partners to continue to lead the newly independent fund as its managing partners.

Image: George Petrocheilos and R. Jacob Vogelstein are the managing partners of venture investment fund Catalio Capital Management LP. MARK DENNIS

BALTIMORE, MD, June 24, 2020 – AsclepiX Therapeutics, Inc., a biopharmaceutical company that uses computational biology to identify potent peptide regulators of vascular homeostasis for the treatment of retinal and other important diseases, today announced that it has closed a $35 million Series A financing led by Perceptive Xontogeny Venture Fund (“PXV Fund”) with participation from the Perceptive Life Sciences Fund, both funds managed by Perceptive Advisors, and existing investors Rapha Capital Management and Barer & Son Capital.

Dear Innovator,

Happy Pride Month! It’s hard to believe it’s almost July. While we’re facing many challenges here in both Washington, DC and in the U.S., the team and I continued to stay busy while working from home over these past few months.

I wanted to take some time to update you on JLABS @ Washington, DC and our activity. Recently I visited the site and was encouraged to see the progress. The construction team has been hard at work even during these tough times and I am very thankful for those working on the front lines, to include our construction workers, during COVID.

In response to medical data highlighting the serious impact of COVID-19 on children’s health, Children’s National is partnering with the National Capital Consortium for Pediatric Device Innovation (NCC-PDI) on a special pitch competition focused on COVID-19 related pediatric medical devices. “Make your Medical Device Pitch for Kids! – COVID-19 edition” is seeking devices that support home health monitoring and telehealth and improve sustainability, resiliency, and readiness in diagnosing and treating children during a pandemic.

Image: https://www.todaysmedicaldevelopments.com

Southeast Life Sciences, the organization behind 400 presentations, 790 funding transactions, and $5.2B in investments from 500 distinct investors is going virtual for a special edition of PitchRounds.

SE PitchRounds is Southeast Life Sciences presentation program. This special PitchRounds event is intended for companies in the southeast United States that are working on products, services, etc. that are addressing a need related to Covid-19. If you have any questions about eligibility, please contact Jason Rupp at jrupp@southeastlifesciences.org